Gross Profit Trends Compared: Vertex Pharmaceuticals Incorporated vs Ascendis Pharma A/S

Vertex vs Ascendis: A Decade of Gross Profit Trends

__timestampAscendis Pharma A/SVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201413983000519428000
Thursday, January 1, 20158118000906794000
Friday, January 1, 201646060001491717000
Sunday, January 1, 201715300002213533000
Monday, January 1, 2018105810002638058000
Tuesday, January 1, 2019133750003615063000
Wednesday, January 1, 202069530005469383000
Friday, January 1, 202142550006670200000
Saturday, January 1, 2022390370007850400000
Sunday, January 1, 20232223230008607000000
Monday, January 1, 20243193830009489600000
Loading chart...

Unleashing the power of data

Gross Profit Trends: Vertex Pharmaceuticals vs Ascendis Pharma

In the competitive landscape of pharmaceuticals, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Vertex Pharmaceuticals Incorporated and Ascendis Pharma A/S from 2014 to 2023. Vertex Pharmaceuticals, a leader in cystic fibrosis treatments, has shown a remarkable growth trajectory, with its gross profit increasing by over 1,500% from 2014 to 2023. In contrast, Ascendis Pharma, known for its innovative endocrinology solutions, experienced a more volatile journey, with a significant spike in 2023, marking a 1,500% increase from its 2014 figures.

Key Insights

  • Vertex Pharmaceuticals: Consistent growth, peaking at $8.6 billion in 2023.
  • Ascendis Pharma: Notable surge in 2023, reaching $222 million.

These trends highlight the dynamic nature of the pharmaceutical industry, where strategic innovation and market positioning can lead to substantial financial gains.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025